Patent · US Active

Coronavirus vaccine

US12208136B2 · kind B2 · utility

0Cited by

108References

28Claims

0Family size

Assignee

BIONTECH SE · DE

Inventors

Alexander Muik · Seeheim-Jugenheim, DE
Kena Anne Swanson · Pearl River, US
Qi Yang · The Woodlands, US
Hui-Zhi Cai · Ridgewood, US
Ugur Sahin · Mainz, DE
Kayvon Modjarrad · Chevy Chase Section Five, US

Key dates

Filing date	Mar 20, 2023
Grant date	Jan 28, 2025
Priority date	—
Expiry date	Mar 20, 2043

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2770/20071
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.